Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at just 30% on average, according to the National Cancer Institute. Factors in the development of AML are diverse with many different drivers. A longtime goal for scientists in this field is finding a single drug that can treat all types of AML.

The findings from recent research studies in pediatric cancer offer hope for drug development.